Shares of InterMune (NASDAQ:ITMN.DL) tumbled by more than 15% today, as the company is suffering from a possible trial data leak from a competitor's idiopathic pulmonary fibrosis drug, which successfully passed its phase 3 trials, and put up solid data. David points to one analyst from Summer Street who quickly came to InterMune's defense, saying that while the two drugs are technically competitors, patients would be cycled between them, given the nature of the IPF disease.

In this segment, Motley Fool health-care analyst David Williamson takes a look at ITMN today, a stock he sees as one that could vary wildly up or down by 50% based on what happens with its drug Esbriet. He talks investors through both scenarios, and also discusses what strong trial data vs. weak could mean for the company, and when investors may see results.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.